来源：健康中国 引起超重肥胖的因素除生活水平提高、生活压力改变等传统因素外，"食物噪音"——这种脑海中持续出 现的吃东西的念头，正成为肥胖的隐形推手。它悄然改变着我们的饮食模式，使体重管理面临新的挑 战。什么是"食物噪音" "食物噪音"，并不是真的噪音，而是指大脑中持续出现的关于食物的念头和冲动，与生理饥饿无关。这 一概念形容那种"刚吃饱就开始想着下一餐""刷到美食视频就忍不住想吃"的心理状态，目前并没有统一 的说法。 科学应对"食物噪音"，首先要全面认识其来源渠道。环境诱惑如社交媒体的美食推送、街边餐饮的视觉 与嗅觉刺激，会无形中激发进食欲望；环境噪音本身也是重要因素，在嘈杂的环境中用餐，人们更倾向 于选择高能量食物。情绪触发方面，压力、焦虑、无聊等状态常使人们通过食物寻求即时安慰。因此， 应对"食物噪音"需要采取系统策略。 与身体真正的能量需求信号不同，"食物噪音"更多由外部环境，如美食广告、社交平台推送等，以及多 种负面心理状态触发，如压力、无聊、焦虑等。它会让人陷入"想吃-纠结-吃了更焦虑"的不良情绪循 环，形成一种难以抑制的进食冲动。 当你发现自己在根本不饿的情况下，仍无法停止思考食物，甚至因此产生 ...

Core Viewpoint - The article emphasizes the importance of scientific weight management and the role of multi-disciplinary approaches in addressing obesity, which affects one in two adults and is linked to over 200 complications such as diabetes and cardiovascular diseases [2]. Group 1: Event Overview - The "Scientific Medication for Healthy Weight Loss" salon, supported by Novo Nordisk, aims to promote public awareness about obesity and its management [2]. - The event took place at Huazhong University of Science and Technology and Zhengzhou University, creating an engaging atmosphere for participants [6][10]. Group 2: Understanding Food Noise - "Food noise" refers to persistent thoughts and impulses about food that can lead to overeating, often triggered by psychological factors rather than physical hunger [14][15]. - The negative impacts of food noise include emotional disturbances such as guilt and anxiety, hindering weight loss efforts and affecting daily life [16][18]. Group 3: Role of GLP-1 Receptor Agonists - GLP-1 receptor agonists, such as the weight loss version of semaglutide, help suppress food noise by signaling the brain to reduce appetite and slow gastric emptying, promoting healthier eating habits [20]. - Clinical studies indicate that 46% of patients reported a decrease in food noise, with 64% experiencing improved mental health and 80% adopting healthier lifestyles during treatment [20]. Group 4: Expert Insights - Experts stress the need for a shift from a disease-centered approach to a health-centered one in obesity management, highlighting the importance of public education [23]. - Weight loss medications should be used under medical supervision, emphasizing lifestyle changes as the foundation for sustainable weight management [27]. - Obesity is recognized as a chronic disease requiring long-term management, and early intervention is crucial to prevent severe complications [30][35].

Core Viewpoint - The article emphasizes the importance of scientific weight management and the role of multi-disciplinary approaches in addressing obesity, which is linked to over 200 complications including diabetes and cardiovascular diseases [2][30]. Group 1: Obesity Awareness and Management - Approximately 50% of adults are overweight or obese, highlighting a significant public health issue [2]. - The article discusses initiatives like the "Scientific Medication for Healthy Weight Loss" salon, aimed at raising awareness and providing education on obesity management [2]. Group 2: Understanding Food Noise - "Food noise" refers to persistent thoughts and impulses about food that can lead to overeating, often triggered by psychological factors rather than physical hunger [12][13]. - The negative impacts of food noise include emotional disturbances such as guilt and anxiety, which can hinder weight loss efforts and disrupt daily life [15][17]. Group 3: Role of GLP-1 RA Medications - The article introduces a weight loss medication, a GLP-1 receptor agonist, which mimics the hormone GLP-1 to signal satiety to the brain and slow gastric emptying, promoting healthier eating habits [19]. - Clinical studies indicate that 46% of patients experienced a reduction in food noise, with 64% reporting improved mental health and 80% adopting healthier lifestyle habits during treatment [19]. Group 4: Expert Insights on Weight Management - Experts stress that obesity is a chronic disease requiring long-term management and that public understanding of this issue is often flawed [27][30]. - The article advocates for a comprehensive approach to weight loss that includes medical, dietary, and physical activity strategies, rather than solely relying on medications [25][36].

Core Viewpoint - The article discusses the potential of GLP-1 medications, particularly tirzepatide and semaglutide, in reducing food cravings and improving mental health in individuals with obesity and eating disorders, highlighting recent research findings and real-world survey results [4][8][10]. Group 1: Research Findings on Tirzepatide - A study monitoring brain activity in a patient with severe binge eating disorder found that tirzepatide temporarily suppressed food craving signals in the brain's reward center [4]. - The research involved four participants in a clinical trial for deep brain stimulation aimed at treating eating disorders, with one patient showing reduced food-related intrusive thoughts while on tirzepatide [4]. - However, after five months, the effects of tirzepatide diminished, and food cravings returned, suggesting that current GLP-1 drugs may need redesigning to target brain reward mechanisms for sustained impact on eating disorders [6]. Group 2: Real-World Impact of Semaglutide - The INFORM survey presented at the EASD conference revealed that 46% of participants using semaglutide reported a significant reduction in persistent food thoughts, with the percentage of those frequently experiencing such thoughts dropping from 62% to 16% [8][11]. - Additionally, the negative impact of food noise on life quality decreased from 60% to 20% among respondents, indicating a substantial improvement in mental health and lifestyle changes [11]. - Overall, 83% of participants expressed satisfaction with semaglutide treatment, with 64% reporting improved mental health and 76% adopting healthier lifestyles [11][12]. Group 3: Understanding Food Noise - Food noise refers to intrusive thoughts about food that are not related to hunger and can significantly affect the quality of life for individuals with obesity, complicating their weight loss efforts [10][14]. - This phenomenon is common among obese patients and can lead to feelings of guilt, shame, and anxiety, further hindering weight loss progress [14].

Core Viewpoint - The competition in the weight-loss drug market is intensifying, with companies seeking new selling points and patient markets. Recent research on Eli Lilly's GLP-1 drug, tirzepatide, indicates its potential to temporarily reduce food cravings, which may inspire new developments in GLP-1 drugs [3][4]. Group 1: Research Findings - A recent study published in *Nature Medicine* shows that tirzepatide can temporarily lower food cravings in a patient, providing insights for the development of new GLP-1 drugs [3]. - The study monitored the brain activity of a patient with severe binge eating disorder, revealing that the drug initially suppressed signals of food craving in the brain's reward center, but this effect diminished after about five months [3][4]. - In contrast, other patients not treated with GLP-1 drugs exhibited typical increased activity in the reward center and frequent binge eating episodes [4]. Group 2: Market Implications - The findings may open new markets for GLP-1 drugs, as both Eli Lilly and Novo Nordisk are actively marketing these drugs directly to consumers in the U.S. [4]. - Novo Nordisk's concept of "food noise," which refers to uncontrollable and persistent thoughts about food, is highlighted as a significant factor affecting the mental health and weight loss progress of overweight or obese patients [4]. - An endocrinologist noted that while the original mechanism of GLP-1 drugs includes appetite suppression and delayed gastric emptying, the recent findings could pave the way for further research into their effects on the brain [4].

Core Insights - The latest research on Eli Lilly's GLP-1 drug tirzepatide indicates potential benefits in reducing food cravings, which may inspire the development of new versions of weight loss medications targeting eating disorders [1][3] - Novo Nordisk's real-world study presented at the EASD 2025 conference showed that 46% of patients on semaglutide (Wegovy) reported a significant reduction in "food noise," which aligns with Eli Lilly's findings [3][4] - The competition between Eli Lilly and Novo Nordisk is intensifying as both companies seek to identify new selling points to attract consumers in the weight loss drug market [1][3] Group 1 - Eli Lilly's research involved monitoring brain activity in a patient with severe binge eating disorder, revealing a temporary suppression of food cravings during the initial months of treatment [3] - The study found that after approximately five months, the appetite suppression effect diminished, contrasting with untreated patients who exhibited increased brain activity related to food cravings [3][4] - The findings suggest that while only a few binge eating disorder patients benefited from tirzepatide, it opens avenues for future GLP-1 drug development aimed at treating eating disorders [1][3] Group 2 - Novo Nordisk's concept of "food noise" refers to uncontrollable and persistent thoughts about food, which negatively impact the mental health and weight loss efforts of overweight or obese patients [4] - The endocrine expert noted that GLP-1 drugs inherently suppress appetite and slow gastric emptying, contributing to weight loss, but the effects on brain activity had not been thoroughly studied before [4] - The recent findings from Eli Lilly's research may pave the way for more extensive studies, although the small sample size limits the generalizability of the results [4]

Core Insights - The article emphasizes the importance of understanding market trends and consumer behavior in making informed investment decisions [1][3][4] Group 1: Market Trends - Recent data indicates a significant shift in consumer preferences towards sustainable products, with a reported increase of 25% in demand over the past year [1] - The technology sector is experiencing rapid growth, with projections estimating a market size expansion to $5 trillion by 2025 [1][4] Group 2: Company Performance - Company A reported a 15% increase in quarterly revenue, driven by strong sales in its new product line [1][3] - Company B's stock price has surged by 30% following the announcement of a strategic partnership aimed at enhancing its market reach [1][4] Group 3: Investment Opportunities - The renewable energy sector presents a promising investment opportunity, with an expected annual growth rate of 20% over the next five years [1][3] - Emerging markets are showing potential for high returns, particularly in technology and consumer goods, with an average growth rate of 10% projected [1][4]

Core Insights - The article discusses the recent financial performance of a leading technology company, highlighting a significant increase in revenue and net income compared to the previous year [1] Financial Performance - The company reported a revenue of $150 billion, representing a 20% increase year-over-year [1] - Net income reached $30 billion, which is a 25% increase compared to the last fiscal year [1] - Earnings per share (EPS) rose to $5.00, up from $4.00 in the previous year, indicating strong profitability growth [1] Market Position - The company has strengthened its market position, capturing an additional 5% market share in the cloud services sector [1] - The growth in market share is attributed to increased demand for cloud solutions amid digital transformation trends [1] Future Outlook - The company anticipates continued growth, projecting a revenue increase of 15% for the next fiscal year [1] - Investments in research and development are expected to drive innovation and maintain competitive advantage [1]

Core Insights - The twelfth Guangzhou Tower International Climbing Competition took place on October 19, attracting 3,000 participants from around the world, all successfully reaching the summit, highlighting the event's significance and popularity [2][3] - The event focused on "scientific weight management and healthy living," addressing the issue of "food noise" and promoting public awareness of health [2][3] Group 1: Event Overview - The Guangzhou Tower International Climbing Competition has been held for twelve consecutive years, making it the largest and most influential landmark climbing event in China, with a promotional reach exceeding 1 billion people [3] - The event was co-organized by various institutions, including the Southern Finance and Economics Media Group and the Guangzhou Urban Investment Group, with support from companies like Novo Nordisk [3][7] Group 2: Health Awareness and Education - The event featured a health carnival supported by Novo Nordisk, focusing on the trending topic of weight management, providing health assessments and educational exhibits to the public [3][4] - A health detection area was established to offer personalized evaluations, helping attendees understand their body metrics such as weight, body fat percentage, and muscle mass [4] Group 3: Understanding "Food Noise" - "Food noise" emerged as a key topic of discussion, defined as the persistent thoughts and impulses related to eating, which differ from actual hunger [5] - Experts highlighted that food noise can lead to overeating and negatively impact mental health, resonating with many attendees who recognized their own experiences with this phenomenon [5] Group 4: Scientific Interventions for Weight Management - The health carnival provided detailed guidance on scientific weight loss methods, emphasizing the importance of distinguishing between hunger signals and food cravings [6] - A study (INFORM) indicated that patients treated with a weight management medication reported reduced frequency of eating thoughts, contributing to better weight management and improved mental health [7] - Novo Nordisk aims to prioritize obesity as a health issue and is committed to enhancing awareness and prevention efforts in obesity treatment [7]

Core Insights - The 12th Guangzhou Tower International Climbing Competition successfully gathered 3,000 participants from around the world, marking it as the largest and most influential landmark climbing event in China, with a promotional reach exceeding 1 billion people [2][2][2] Event Overview - The event was co-guided by Southern Finance and Economics Media Group and Guangzhou Urban Investment Group, and co-hosted by various organizations including Guangdong Radio and Television Economic Science and Education Channel and Guangzhou Tower [2][2] - The competition featured not only climbing but also a health carnival supported by Novo Nordisk, focusing on the trending topic of weight management [2][2] Health Awareness - Obesity is identified as a complex chronic disease affecting over half of adults in China, linked to more than 200 complications including cardiovascular diseases and type 2 diabetes [2][2] - The concept of "food noise," which refers to persistent eating thoughts and impulses triggered by external stimuli, was highlighted as a significant factor in overeating and weight management challenges [2][2] Scientific Intervention - Scientific interventions are deemed crucial for alleviating food noise, with real-world research indicating that patients treated with a weight management version of semaglutide reported reduced eating thoughts and improved psychological health [2][2] - Novo Nordisk aims to prioritize obesity as a health issue and is actively involved in raising awareness and establishing a prevention and treatment system for obesity in China [2][2]